Cardiogenic shock complicating peripartum cardiomyopathy benefits from combination therapy with levosimendan and bromocriptine
Thus, the combination therapy with LS and BR seems to be a safe and potentially beneficial therapeutic concept for the treatment of PPCM patients with CS. As experimental PPCM mouse data suggest that treatment of PPCM patients in CS with LS alone may worsen cardiac function by enhancing the PRL/PAI-1-dependent pathomechanism, treatment of LS in PPCM patients should always be accompanied by BR treatment.
Authors
- Manuel List
- Birgit Piep
- Tobias J. Pfeffer (ORCID: https://orcid.org/0000-0002-9130-9470)
- Susanna Haidari (ORCID: https://orcid.org/0000-0002-8506-8578)
- Theresia Kraft (ORCID: https://orcid.org/0000-0002-8386-8088)
- Ante Radocaj (ORCID: https://orcid.org/0000-0003-4518-6323)
- Denise Hilfiker‐Kleiner (ORCID: https://orcid.org/0000-0001-6065-9649)
- Martina Kasten
- Dominik Berliner (ORCID: https://orcid.org/0000-0002-5710-3540)
- Sergej Erschow
- Natalie Weber (ORCID: https://orcid.org/0000-0002-2302-1045)
- Jan-Thorben Sieweke
- Andreas Schäfer
- Faramarz Matinmehr
- Melanie Ricke-Hoch
- Marian Stojanovski
- Lukas Eisen
- Johann Bauersachs
Institutions
- Medizinische Hochschule Hannover (DE)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1093/ejhf/xuag002
- Citations
- 1
- Primary Topic
- Cardiovascular Issues in Pregnancy
- Type
- article
- Field-Weighted Citation Impact
- 30.07